A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.

Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J
Crit Care Med. 2010 38 (8): 1685-94

PMID: 20562702 · DOI:10.1097/CCM.0b013e3181e7c5c9

MeSH Terms (22)

Adult Aged Cytokines Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hospital Mortality Humans Infusions, Intravenous Male Middle Aged Multiple Organ Failure Probability Pulse Therapy, Drug Reference Values Risk Assessment Sepsis Sulfonamides Survival Analysis Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities:

Links